Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Metagenomi Therapeutics, Inc.MGX · Entity 7270 | Director | December 05, 2025 | December 08, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Metagenomi Therapeutics, Inc.
Report date December 05, 2025 · Filed December 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,510,960 |
Reported balance
After 2025-12-05 transaction · row 1
1 source rowRow 1 · 2025-12-05 · Sale · Disposed 3,830 · Balance 2,510,960 F1: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2025 Filed Dec 8, 2025 18:56 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 3,830 | $1.77 | $6,786.38 |
DisclosureSEC source: 0001193125-25-310971 · ownership.xml · nonDerivative · entry 1 Thomas Brian C. · CIK 0001996097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,510,960 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person on April 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| September 05, 2025 Filed Dec 2, 2025 00:34 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 2,701 | $1.81 | $4,888.81 |
DisclosureSEC source: 0001193125-25-304221 · ownership.xml · nonDerivative · entry 1 Thomas Brian C. · CIK 0001996097 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,514,790 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the Reporting Person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the Reporting Person. Read SEC document |
| June 06, 2025 Filed Jun 9, 2025 22:50 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | SaleCommon Stock | 10,785 | $1.75 | $18,873.75 |
DisclosureSEC source: 0000950170-25-083947 · ownership.xml · nonDerivative · entry 1 Thomas Brian C. · CIK 0001996097 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,517,491 F1 · kind: These shares of common stock were automatically sold for the purpose of satisfying the reporting person's tax withholding obligations upon the vesting of certain restricted stock units granted to the reporting person on April 1, 2024, and does not represent a volitional trade by the reporting person. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 15:58 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 196,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0000950170-25-050102 · ownership.xml · derivative · entry 2 Thomas Brian C. · CIK 0001996097 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,000 Underlying: Common Stock · 196,000 shares Expires 2035-03-31 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 15:58 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-050102 · ownership.xml · nonDerivative · entry 1 Thomas Brian C. · CIK 0001996097 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,528,276 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2026, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:00 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantStock Option (Right to Buy) · Derivative | 500,323 | $0.00 Strike: $10.82 | $0.00 |
DisclosureSEC source: 0000950170-24-041449 · ownership.xml · derivative · entry 2 Thomas Brian C. · CIK 0001996097 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,323 Underlying: Common Stock · 500,323 shares Expires 2034-03-31 F2 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on April 1, 2025, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| April 01, 2024 Filed Apr 4, 2024 00:00 UTC | Metagenomi Therapeutics, Inc. MGX · Entity 7270 | GrantCommon Stock | 118,992 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-041449 · ownership.xml · nonDerivative · entry 1 Thomas Brian C. · CIK 0001996097 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,496,276 F1 · shares: These shares represent restricted stock units ("RSUs"). 25% of the RSUs shall vest on June 5, 2025, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.